ISEQ up as Elan drug gets the nod
The ISEQ index of shares continued its upward trend this morning, gaining 36.17 to 7387.98.
The hike came as Elan Corporation plc and Biogen Idec announced that they received approval from the European Commission to market Tysabri as a treatment for multiple sclerosis (MS). Elan shares were up 12c to €13.37 this morning.